Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Tianjin KingYork and Innovata Announce $190 Million Asthma JV

publication date: Jan 2, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Tianjin KingYork Group Co. and Innovata HK Limited have formed a JV that will be located in Tianjin Economic-Technological Development Area (TEDA). The new company, which will be known as Tianjin Kinnovata Pharma, will produce powder inhalation drugs for asthma and COPD. The JV has been funded with $9.6 million initially. Over the longer term, the partners plan to invest $190 million in the project. The partners were advised by Morrison & Foerster, an international law firm specialized in life sciences, who also revealed that the JV expects to eventually attain revenues of more than 1 billion RMB ($160 million). More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners